Camrelizumab plus anlotinib for MMRd endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two medicines (camrelizumab and anlotinib) for endometrial cancer that has spread back or continued and has specific tumor gene changes called MMRd. It may help shrink tumors or control the disease by activating the immune system and blocking cancer growth signals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer that has come back or spread, and you’ve had 1 to 3 prior treatment rounds (including at least one platinum chemotherapy).
- Your tumor has been tested and confirmed to be MMRd, including an MLH1 methylation change.
- Your cancer is measurable on scans and is considered not safely curable with surgery and/or radiation (or you can’t tolerate chemotherapy).
- Your general health is good enough for treatment (ECOG 0–2), and you’re expected to live at least 12 weeks.
- Your blood counts and organ function are within required ranges (including enough white cells, platelets, and hemoglobin).
- You can sign consent and agree to study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This trial tests a new drug combination (sacituzumab tirumotecan plus pembrolizumab) against pembrolizumab alone for people with a specific type of advanced or recurrent endometrial cancer that has normal mismatch repair function. It aims to see which treatment works better.
This trial tests a combination of two drugs, avelumab (an immunotherapy) and M1774, in people with a specific type of endometrial cancer that has an ARID1A gene mutation. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of two drugs, camrelizumab (an immunotherapy) and fluzoparib (a PARP inhibitor), for people with a specific type of endometrial cancer that has a TP53 gene mutation. It may offer a new option for advanced or recurrent disease after limited prior treatment.
This early-phase trial tests pembrolizumab combined with ataluren for people with metastatic colorectal cancer that has either dMMR or pMMR, and for metastatic dMMR endometrial cancer. The goal is to see whether this combination can shrink tumors or improve outcomes for cancers with specific mismatch repair (MMR) features.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.